When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?
- PMID: 28113025
- DOI: 10.1200/JCO.2016.71.0103
When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?
Comment in
-
Reply to V. Amoroso et al.J Clin Oncol. 2017 May 1;35(13):1488-1489. doi: 10.1200/JCO.2017.71.3875. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113028 No abstract available.
Comment on
-
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621394 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
